

This is a pre print version of the following article:

In Vivo Melanoma Cell Morphology Reflects Molecular Signature and Tumor Aggressiveness / Marconi, Alessandra; Quadri, Marika; Farnetani, Francesca; Ciardo, Silvana; Palazzo, Elisabetta; Lotti, Roberta; Cesinaro, Anna Maria; Fabbiani, Luca; Vaschieri, Cristina; Puviani, Mario; Magnoni, Cristina; Kaleci, Shaniko; Pincelli, Carlo; Pellacani, Giovanni. - In: JOURNAL OF INVESTIGATIVE DERMATOLOGY. - ISSN 0022-202X. - 142:8(2022), pp. 2205-2216.e6. [10.1016/j.jid.2021.12.024]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

14/05/2026 09:43

(Article begins on next page)



## In Vivo Melanoma Cell Morphology Reflects Molecular Signature and Tumor Aggressiveness

Journal:	<i>Journal of Investigative Dermatology</i>
Manuscript ID	JID-2021-0439
Article Type:	Original Article
Date Submitted by the Author:	19-May-2021
Complete List of Authors:	<p>Marconi, Alessandra; University of Modena and Reggio Emilia, Surgical, Medical, Dental and Morphological Science</p> <p>Quadri, Marika; University of Modena and Reggio Emilia, Laboratory of Cutaneous Biology, Department of Surgical, Medical, Dental and Morphological Sciences</p> <p>Farnetani, Francesca; University of Modena and Reggio Emilia, Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine</p> <p>Ciaro, Silvana; University of Modena and Reggio Emilia, Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine</p> <p>PALAZZO, ELISABETTA; University of Modena and Reggio Emilia, Laboratory of Cutaneous Biology, Department of Surgical, Medical, Dental and Morphological Sciences</p> <p>Lotti, Roberta; University of Modena and Reggio Emilia, Laboratory of Cutaneous Biology, Department of Surgical, Medical, Dental and Morphological Sciences</p> <p>Cesinaro, Anna ; Azienda Ospedaliero-Universitaria di Modena Policlinico di Modena, Department of Pathology</p> <p>Fabbiani, Luca; University of Modena and Reggio Emilia, Department of medical and surgical sciences</p> <p>Vaschieri, Cristina ; University of Modena and Reggio Emilia, DermoLAB, Department of Surgical, Medical, Dental and Morphological Science</p> <p>Puviani, Mario; Sassuolo Hospital, Unit of Dermatology and Surgical Dermatology</p> <p>Magnoni, Cristina; University of Modena and Reggio Emilia, Dermatology Unit; Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine</p> <p>Kaleci, Shaniko; Università degli Studi di Modena e Reggio Emilia, Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Science with Interest Transplant, Oncological and Regenerative Medicine</p> <p>Pincelli, Carlo; University of Modena and Reggio Emilia, Laboratory of Cutaneous Biology, Department of Surgical, Medical, Dental and Morphological Sciences</p> <p>Pellacani, Giovanni; University of Modena and Reggio Emilia, Dermatology; University of Rome La Sapienza, Dermatology Clinic, Department of Clinical Internal, Anesthesiology and Cardiovascular</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Sciences
Keywords:	Melanoma, Imaging, Microscopy, Cancer Biology, Gene Transcription

SCHOLARONE™  
Manuscripts

# In Vivo Melanoma Cell Morphology Reflects Molecular Signature and Tumor Aggressiveness

Alessandra Marconi<sup>1\*</sup> (ORCID: 0000-0002-5667-5766), Marika Quadri<sup>1\*</sup> (ORCID: 0000-0001-7619-660X), Francesca Farnetani<sup>2</sup> (ORCID: 0000-0001-7088-9077), Silvana Ciardo<sup>2</sup> (ORCID: 0000-0002-2381-2189), Elisabetta Palazzo<sup>1</sup> (ORCID: 0000-0002-0812-5524), Roberta Lotti<sup>1</sup> (ORCID: 000-0003-2126-4147), Anna Maria Cesinaro<sup>3</sup> (ORCID: 0000-0001-6807-8152), Luca Fabbiani<sup>4</sup> (0000-0002-0104-5249), Cristina Vaschieri<sup>1</sup> (ORCID: 0000-0001-6434-2681), Mario Puviani<sup>5</sup> (ORCID: 0000-0003-1792-2581), Cristina Magnoni<sup>2</sup> (0000-0002-6081-4925), Shaniko Kaleci<sup>2</sup> (0000-0002-1166-2961), Carlo Pincelli<sup>1</sup> (ORCID: 0000-0003-4416-2637) and Giovanni Pellacani<sup>2,6</sup> (ORCID: 0000-0002-7222-2951)

<sup>1</sup> DermoLAB, Department of Surgical, Medical, Dental and Morphological Science, University of Modena and Reggio Emilia, Modena, Italy

<sup>2</sup> Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy

<sup>3</sup> Department of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy.

<sup>4</sup> Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy

<sup>5</sup> Unit of Dermatology and Surgical Dermatology, Sassuolo Hospital, Sassuolo, Modena, Italy.

<sup>6</sup> Dermatology Clinic, Department of Clinical Internal, Anesthesiology and Cardiovascular Sciences, La Sapienza University of Rome, Italy

\* The authors contributed equally to this work

1  
2  
3 **Corresponding author:** Alessandra Marconi, DermoLAB, Department of Surgical, Medical,  
4 Dental and Morphological Science, University of Modena and Reggio Emilia, via Del Pozzo  
5  
6  
7 71, 41124, Modena, Italy; Tel.: +39 059 4222812; Fax: +39 059 4224271; Mail:  
8  
9 alessandra.marconi@unimore.it  
10  
11  
12  
13  
14

15 **Short Title:** Bio-molecular characterization of RCM-melanoma subtypes  
16

17 **Abbreviations:** Reflectance Confocal Microscopy (RCM), Dendritic cell melanoma (DC)  
18  
19 Round Cell melanoma (RC), Dermal Nest melanoma (DN), Combined type melanoma (CT).  
20  
21  
22  
23  
24

## 25 **ABSTRACT**

26  
27 Melanoma is the deadliest type of skin cancer, characterized by high cellular heterogeneity  
28 which contributes to therapy resistance and unpredictable disease outcome. Recently, by  
29 correlating Reflectance-Confocal-Microscopy (RCM) morphology with histopathological type,  
30 we identified four distinct melanoma-subtypes: dendritic-cell (DC), round-cell (RC), dermal-  
31 nest (DN), and combined-type (CT) melanomas. In the present study, each RCM melanoma-  
32 subtype expressed a specific biomolecular profile and biological behavior *in vitro*. Markers of  
33 tumor aggressiveness, including Ki67, MERTK, nestin and stemness markers, were highest in  
34 the most invasive CT and DN melanomas, as compared to DC and RC. This was also confirmed  
35 in multicellular tumor spheroids. Transcriptomic analysis showed a modulation of cancer-  
36 progression-associated genes from DC to CT melanomas. The switch from E- to N-cadherin  
37 expression proved the epithelial-to-mesenchymal transition from DC to CT subtypes. The DN  
38 melanoma was predominantly located in the dermis, as also shown in skin reconstructs. It  
39 displayed a unique behavior and a molecular profile associated with a high degree of  
40 aggressiveness. Altogether, our results demonstrate that each RCM-melanoma subtype has a  
41 distinct biological and gene expression profile, related to tumor aggressiveness, confirming that  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

RCM can be a dependable tool for *in vivo* detecting different types of melanoma and for early diagnostic screening.

## Introduction

Melanoma is an extremely aggressive skin cancer consisting of several cell populations that show diverse genotypic and phenotypic features, signalling pathway, biological behaviour, and response to therapy, suggesting the existence of a heterogeneous family of diseases rather than a unique entity (Scolyer et al., 2011). Melanoma is characterized by high metastatic capacity, resistance to conventional chemotherapy and in part to new targeted drugs (Rodriguez-Cerdeira et al., 2017). Given its threatening potential, early detection remains the key factor in lowering melanoma-associated mortality. Classification is important for tumor diagnosis and prognosis. Melanoma is currently classified based on different parameters such as histopathological type, vertical growth, spreading to nearby lymph nodes or any other organs (Arrangoiz et al., 2016). However, it has become clear that this classification and staging system fail to account for different progression models of melanoma and to pre-select patients for a specific treatment (Broekaert et al., 2010). This implies the need for new criteria and methodology to classify melanoma.

Reflectance-confocal-microscopy (RCM) is an emerging technology for the non-invasive analysis of skin tissue in real-time and at near-histopathological resolution (Fink and Haenssle, 2016). Recently, we proposed the existence of four distinct melanoma-subtypes based on the correlation between RCM-observed cell-morphology and histopathological/patients' clinical features: 1) Dendritic-Cell (DC) with a predominant population of dendritic-cells in the epidermal layer; 2) Round-Cell (RC) mostly composed of large roundish-cell population in the epidermal layer and dermal-epidermal junction (DEJ); 3) Dermal-Nest (DN) characterized by the presence of a dermal cerebriform nesting in the dermis; 4) Combined-Type (CT) which shows a

1  
2  
3 combination of all three confocal patterns (Pellacani et al., 2014). Previous work showed a  
4 correlation between patients' features and melanoma-subtypes, suggesting that RCM cell-  
5 morphology may be associated with different tumor stage and biological behavior (Graziottin et  
6 al., 2016). Accordingly, a biological heterogeneity among RCM-subtypes based on the different  
7 expression of tumor-associated biomarkers was recently shown (Beretti et al., 2018). It is known  
8 that specific genetic alterations are associated with precise clinical and histopathological features  
9 of melanoma, indicating that they may be helpful in refining existing disease classification  
10 (Whiteman et al., 2011). Yet, the existence of a close correlation between RCM-melanoma  
11 subtypes, genetic signature and biological behavior remains to be clarified.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23  
24 In this work, we detected significant modifications in the expression of specific melanoma  
25 biomarkers in the RCM-subtypes and we present evidence that the four melanoma-groups display  
26 different genetic profile and biological behaviour *in vitro*, which closely correlate with tumor  
27 aggressiveness.  
28  
29  
30  
31  
32  
33  
34

## 35 Results

### 36 RCM-subtypes reflect patient/tumor characteristics.

37  
38 90 patients, with a median age of 60.9 years, were analysed in this study (Table 1).  
39 Representative clinical, histopathological and RCM images are illustrated in Figure 1a-f. DC  
40 melanomas were mainly of the RGP type (92%), with a Breslow index (BI) of less than 1mm  
41 and a mitotic index (MI) between 0 and 1 (both 96%). Moreover, DC presented significantly  
42 less BRAF<sup>V600E</sup> mutations than the other RCM subtypes. An increase in tumor thickness (BI)  
43 was found in RC melanomas, as compared to DC. RC were either of the RGP or VGP type  
44 (56% and 44% respectively), despite their low MI (96% between 0-1). On the other hand, CT  
45 and DN were mostly of the VGP type (96% and 93% respectively), showing high MI (40% 2-  
46 5mm). DN melanomas were significantly thicker than the other RCM-types (5.8mm). 36% of  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 patients with DC type had a previous history of melanoma and 40% of them relapsed or  
4 developed new melanomas, as compared to the other RCM subtypes. However, none of DC  
5 types progressed to metastases. On the contrary, CT and DN significantly tended to metastasize,  
6 as revealed by the percentage of positive sentinel lymph nodes (32 and 27% respectively) and  
7 metastases at 0-5 years (20 and 34 %, respectively).  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 **RCM-morphology correlates with aggressiveness, stemness markers expression and**  
18 **biological behavior *in vitro*.**  
19

20  
21 To analyze the growth fraction in each RCM-subtype, the expression of Ki67 proliferation-  
22 marker was evaluated both in the epidermis and dermis (Figure 2a). DC melanomas showed the  
23 expression of Ki67 exclusively in the epidermis, whereas DN melanomas showed it in the  
24 dermis. By comparing DC and RC melanomas, the expression of Ki67 in RC was mainly  
25 localized in the epidermis with fraction of positive cells in the dermis, suggesting its more  
26 aggressive behavior compared to DC melanoma. Conversely, CT expressed elevated levels of  
27 Ki67 both in epidermis and dermis.  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 C-MER proto-oncogene tyrosine kinases (MERTK) and the intermediate filament Nestin are  
38 associated with melanoma aggressiveness and progression (Schlegel et al., 2013; Klein et al.,  
39 2007). The expression of these markers significantly raised from DC to CT/DN melanomas,  
40 while no differences were observed between CT and DN (Figure 2a).  
41  
42  
43  
44  
45  
46

47 The expression of Hypoxia transcription factor (HIF) 1 $\alpha$ , which is known to stimulate  
48 angiogenesis (Widmer et al., 2013), was significantly higher in RC, as compared to the other  
49 RCM-subtypes. Moreover, the expression of SOX-10, known to affect melanoma cell  
50 proliferation, survival, and invasion (Graf et al., 2014), significantly increased from DC to CT-  
51 DN melanomas (Figure 2a).  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The melanoma-initiating-cells (MICs), significantly contributing to initiation, metastasis, and  
4 recurrence of melanoma, consist of a cell subpopulation expressing various markers such as the  
5 ABC-transporter-5 (ABCB5) (Chartrain et al., 2012), CD133 (Monzani et al., 2007), SOX-2  
6 (Santini et al, 2014) and CD271 (Boiko et al., 2010). ABCB5 expression significantly increased  
7 from DC to CT-DN melanomas, whereas no differences were found between CT and DN. On  
8 the contrary, SOX-2 and CD133 were significantly more expressed in DN. CD271 expression  
9 considerably increased from DC to RC, while it decreased from RC to CT/DN melanomas. The  
10 latter finding is not unexpected given the controversial role of CD271 in melanoma. Despite it  
11 is considered a MICs marker, CD271 downregulation has been shown to promote melanoma  
12 progression and invasion (Saltari et al., 2016) (Figure 2b).

13  
14 To define the biological behaviour of RCM-subtypes, freshly-isolated cells from melanoma  
15 biopsies were seeded as Multicellular-Tumor-Spheroids (MCTSs) (Figure 2c). While CT and  
16 DN cells were able to generate spheroids, DC and RC failed to form compact MCTSs , probably  
17 due to their less proliferative capacity (Figure 2d). Consistently, CT and DN showed a greater  
18 proliferative ability than DC and RC (Figure 2e). Altogether, these data suggest that CT and  
19 DN contain the most aggressive tumor cell populations, given their major expression of  
20 aggressiveness-associated markers and their higher proliferative capacity *in vitro*. Notably, DN  
21 showed higher expression levels of the MIC's markers CD133 and SOX-2, as compared the  
22 other RCM-subtypes, indicating the peculiarity of this melanoma subtype.

### 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 **RCM-subtypes display different gene expression profiles.**

50  
51 To characterize the RCM-subtypes at the molecular level, a transcriptome analysis associated  
52 with cancer-progression was performed. Using DAVID Functional-Association-Tool, we  
53 analyzed the differentially expressed genes among groups and a Biological Process (BP)  
54 enrichment was obtained for each RCM-subtypes (Figure 3a). In detail, we observed a  
55  
56  
57  
58  
59  
60

1  
2  
3 progressive increase in extracellular-matrix (ECM) remodeling, angiogenesis, and  
4 inflammation BP terms from DC to CT melanomas. Conversely, a downregulation of the genes  
5 involved in cell-adhesion was found from DC to CT. On the other hand, DN gene expression  
6 profile appeared to deviate from the other RCM-subtypes, showing a distinct pattern of gene  
7 expression associated with ECM-remodeling, angiogenesis, inflammation, and cell-adhesion.  
8 Moreover, a modulation of cancer-associated transcription factor (TF) gene expression among  
9 the different groups was identified. SMAD and BMP signaling pathways, stem cell  
10 differentiation, bicellular-tight-junction assembly and positive regulation of cell differentiation  
11 BPs were the most significantly modulated TF-associated-genes. This is consistent with the  
12 functional role of those genes in tumor progression (Schlegel et al., 2013; Caramel et al., 2013;  
13 Rusciano, 2000).

14  
15 We further evaluated the gene expression profile of the RCM-subtypes as compared to the less  
16 aggressive DC type (Figure 3b-c). By uploading each comparison into Venny 2.1, we identified  
17 55 (25.6%) and 60 genes (27.97%) that were specifically upregulated in RC and CT vs DC,  
18 respectively, while only 16 genes (7.4%) were upregulated in DN vs DC. Conversely, 128 genes  
19 (68.5%) were downregulated in DN vs DC, while only 7 (2.7%) and 18 (6.8%) genes were  
20 downregulated in RC vs DC and CT vs DC, respectively. Subsequently, for each comparison,  
21 we analyzed the specific pathways belonging to the unique or common gene profile, by  
22 uploading the corresponding gene list on PANTHER Classification-System (Figure S1-S2,  
23 Figure 3b-c). Slight differences in gene modulation were found in RC vs DC. Up and down-  
24 regulated genes in this comparison were mainly involved in the first steps of inflammation  
25 (mediated by chemokine/cytokines), regulation of cytoskeleton and cadherin signaling  
26 pathway. A modulation of genes involved in integrin and cadherin signaling pathway and  
27 angiogenesis were found in CT vs DC, suggesting an increase of tumor aggressiveness in CT  
28 compared to DC/RC. Moreover, we found a variation in genes involved in the advanced steps  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of inflammation (B and T-cell activation), and angiogenesis in DN vs DC melanomas,  
4  
5 suggesting that DN could be a highly aggressive tumor. Survivin is considered a biomarker of  
6  
7 poor prognosis in melanoma (Takeuchi et al., 2005), and the expression of CXCL8 positively  
8  
9 correlates with tumor progression (Ugurel et al., 2001), while CD271 downregulation has been  
10  
11 associated to melanoma progression and invasion (Saltari et al., 2016). The expression of  
12  
13 *BIRC5* (Survivin), and *CXCL8* mRNA significantly raised from DC to CT-DN melanomas,  
14  
15 suggesting a progressive increase in tumor aggressiveness. On the other hand, *NGFR* mRNA  
16  
17 (CD271) increased from DC to RC and subsequently decreased from RC to CT/DN in a  
18  
19 statistically significant manner, confirming the immunohistochemical results (Figure 3d).  
20  
21  
22  
23  
24  
25

### 26 **RCM-morphology reflects tumor aggressiveness and progression stage.**

27  
28 The above results indicate that RC subtypes show intermediate characteristics between DC and  
29  
30 CT melanomas. To further confirm this finding, we analysed the most significant pathways in  
31  
32 RC vs DC and CT vs RC subtypes (Figure S3; Figure 4a-b). As expected, only few genes were  
33  
34 significantly modulated in RC vs DC melanomas (Figure 4a). In detail, TGF- $\beta$  and WNT-  
35  
36 Signaling pathway associated genes were found to be upregulated in RC, as compared to DC  
37  
38 melanomas. Consistently, TGF- $\beta$  isoforms promote tumor invasiveness *in vitro* (Javelaud et  
39  
40 al., 2008), while WNT-signaling plays an important role in the crosstalk between key oncogenic  
41  
42 pathways involved in melanoma development and progression (Gajos-Michniewicz and  
43  
44 Malgorzata, 2020). The interactions between chemokine and their receptors can independently  
45  
46 protect against tumor development and growth or they can stimulate melanoma tumor  
47  
48 progression and metastasis (Richmond et al., 2009). In our context, both up and downregulation  
49  
50 of genes involved in this type of inflammation were found. Moreover, the upregulation of  
51  
52 *CXCL8* in RC melanomas confirmed their more aggressive behavior, as compared to DC.  
53  
54  
55  
56  
57

58 By comparing CT and RC melanomas, we found a substantial gene modulation related to  
59  
60

1  
2  
3 integrins and cadherins signaling pathways (Figure S3; Figure 4b). During melanoma  
4 progression, a modulation of cell-adhesion molecules is known to guide the phenotype  
5 switching that promote cell migration (Haass et al., 2005). High levels of  $\beta 1$  and  $\beta 3$ -integrin  
6 are known to promote melanoma transition from RPG to VPG type (Ramakrishnan et al., 2006),  
7 while  $\alpha \nu \beta 3$  and  $\alpha \nu \beta 5$ -integrins are involved in angiogenesis, being upregulated on endothelial  
8 cells during tumor neovascularization (Eskens et al., 2003). Moreover, the T-cadherin  
9 downregulation (*CDH13* gene) was found to influence migration and invasion (Bosserhoff et  
10 al., 2013). Genes related to  $\beta 3$ -integrin and to angiogenesis were upregulated while *CDH13*  
11 was downregulated in CT melanomas (Figure S4; Figure 3b), highlighting its more aggressive  
12 behavior, as compared to RC.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Recently, we have shown that *CD271* downregulation plays a role in promoting melanoma  
27 progression and invasion, at least in part because of the lack of cell-cell-adhesion molecule  
28 (Saltari et al., 2016). *CD271* expression increased from DC to RC and, subsequently, turned off  
29 from RC to CT (Figure 2b and Figure 3d). In RCM-subtypes with different thickness, *CD271*  
30 expression directly correlated with BI in the less aggressive RCM subtypes, while it inversely  
31 correlated in more advanced tumors (BI >1 mm) (Figure 4c). At the same time, we found that  
32 the E-cadherin expression significantly decreased from DC to CT, suggesting a progressive loss  
33 of epithelial cell-adhesion molecules, which was paralleled by an increase of N-cadherin from  
34 CT to DC melanomas (Figure 4e).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 **CT and DN subtypes show a different gene expression profile and biological behavior *in***  
50 ***vitro*.**  
51

52 Data reported here suggest that CT and DN are the most aggressive tumors, and DN reveals a  
53 unique gene expression profile. To evaluate the difference between these two types of tumors,  
54 the up and downregulated genes in CT vs DN were analysed by PANTHER and then clustered  
55  
56  
57  
58  
59  
60

1  
2  
3 according to the most significant pathways involved (Figure S4; Figure 5a). Several genes were  
4  
5 up and downregulated in CT vs DN, highlighting the differences between these tumor types.  
6  
7 To further investigate the difference between CT and DN, their function was analysed *in vitro*  
8  
9 by using 3D-models (Figure S5; Figure 5b). The *in vitro* invasion assay revealed that DN  
10  
11 melanomas were significantly more invasive than CT (Figure 5c-d). Moreover, DN cells  
12  
13 reached a longer distance from spheroid, as compared to CT cells (Figure 5f). In melanoma skin  
14  
15 reconstructs, CT cells were observed at the DEJ. Contrariwise, DN cells were able to growth  
16  
17 only when seeded directly into the dermis, (Figure 5g), displaying a high proliferative capacity,  
18  
19 as shown by the % of Ki67 positive cells (Figure 5h). E-cadherin was scarcely detected in DN  
20  
21 melanoma, which expressed elevated levels of N-cadherin, as compared to CT. The higher  
22  
23 expression of  $\alpha 4$  and  $\alpha 7$ -integrin in DN compared to CT confirmed the greater invasive  
24  
25 behavior of this tumor. Additionally, DN expressed significantly increased levels of SOX-2  
26  
27 compared to CT, confirming its more undifferentiated state (Figure 5h). Moreover, while  
28  
29 invading cells from DN-spheroids expressed higher level of  $\alpha 4$ -integrin, confirming the  
30  
31 aggressiveness of this tumor type, CD271 was scarcely detectable in these cells (Figure 5i).  
32  
33  
34  
35  
36  
37  
38  
39  
40

## 41 Discussion

42  
43 Melanoma progression depends on diverse phases where the stepwise acquisition of genetic  
44  
45 abnormalities contributes to the increase of aggressiveness (Thompson et al., 2005).  
46  
47 Distinguishing between these stages may be important to have a more accurate diagnosis and  
48  
49 prognosis. It has been shown that RCM-subtypes might reflect specific clinical patterns. DC is  
50  
51 mainly associated to a slow-intra-epidermal growing tumor, mainly characterized by single cell  
52  
53 vs. nest proliferation, while RC shows a predominantly horizontal pattern of growth with a  
54  
55 tendency to form nests and to infiltrate the dermis. Conversely, DN shows a rapid pattern of  
56  
57 growth with higher BI (Pellacani et al., 2014). Consistently, our study demonstrates a  
58  
59  
60

1  
2  
3 progressive increase of the clinical pattern severity going from DC to CT-DN melanomas.  
4  
5 Moreover, DC develop more melanomas in time or relapses than the other RCM-subtypes,  
6  
7 suggesting an association with a prolonged sun exposure. Conversely, CT and DN metastasize  
8  
9 at significantly higher rate, as compared to DC or RC melanomas.  
10  
11

12 By the analysis of the expression of several biomarkers, the molecular signature, and the  
13  
14 biological behaviour *in vitro*, we have defined a specific bio-molecular profile for each RCM-  
15  
16 melanoma subtype (Figure S6). The first step of melanoma progression is RGP, characterized  
17  
18 by the proliferation of atypical melanocytes in the epidermis. This is followed by VGP, which  
19  
20 consists of proliferating tumor cells in the dermis (Clark et al., 1969). In this context, Ki67-  
21  
22 positive cells define tumor proliferation compartments in melanomas. Moreover, the correlation  
23  
24 of Ki67 expression and MI is used as melanoma prognostic marker (Phyllis et al., 2006). The  
25  
26 presence of proliferating cells in dermis and high MI in CT and DN suggests the more  
27  
28 aggressiveness of this tumor compared to DC/RC subtypes. Additionally, the expression of a  
29  
30 small fraction of Ki67 positive cells in the dermis in RC vs DC, suggests that RC is more  
31  
32 advanced tumor than DC.  
33  
34  
35  
36

37 The expression of aggressiveness-biomarkers (MERTK, Nestin), as well as the high levels of  
38  
39 *CXCL8* and *BIRC5* mRNA underlined the increase of aggressive features from DC to CT/DN  
40  
41 melanomas, which was also confirmed by their proliferative capacity *in vitro*. Additionally, CT  
42  
43 and DN were characterized by more elevated levels of ABCB5, in line with the chemo-  
44  
45 resistance proprieties of these tumor types (Chartrain et al., 2012).  
46  
47  
48

49 The progressive modulation of cancer-progression-associated genes, such as ECM-remodeling,  
50  
51 angiogenesis and inflammation, from DC to CT melanoma strongly suggests the switch in term  
52  
53 of aggressiveness between these tumor types. Consistently, SMAD and TGF- $\beta$ -signaling,  
54  
55 BMP-ligands, the modulation of specific adhesion-molecules and differentiation-associated  
56  
57 genes strongly correlate with tumor aggressiveness and progression (Schlegel et al., 2013,  
58  
59  
60

1  
2  
3 Caramel et al., 2013; Rusciano, 2000). Cancer-associated TF-gene expression involved in these  
4  
5 pathways was significantly modulated between the different RCM-subtypes, indicating an  
6  
7 increase of aggressiveness and invasive capacities between these tumor types. DC melanoma  
8  
9 may represent a well-differentiated tumor with limited abilities of proliferation and invasion,  
10  
11 as shown by the significantly low expression of tumor aggressiveness/invasiveness-associated  
12  
13 genes. Conversely, since RC melanoma was characterized by both RGP and VGP, we speculate  
14  
15 that it may present an intermediate degree of aggressiveness between the well-differentiated  
16  
17 DC-type and the most invasive CT-DN melanomas. Giving these characteristics of RC, we  
18  
19 speculate that the higher expression of HIF-1 $\alpha$  in this melanoma-subtype could be necessary  
20  
21 for the acquisition of the invasive properties and the need of new vascularization (Widmer et  
22  
23 al., 2013). Moreover, the increased CD271 expression in RC could be instrumental in favoring  
24  
25 its epidermis-to-dermis transition (Saltari et al., 2016).

26  
27  
28  
29  
30 TGF- $\beta$ -superfamily signaling as well as the modulation of specific adhesion molecules and  
31  
32 cytoskeletal regulation play an important role in promoting invasiveness *in vitro* (Schlegel et  
33  
34 al., 2013, Caramel et al., 2013). We found a significant modulation of the genes associated to  
35  
36 cytoskeletal regulation, cadherin and TGF- $\beta$  signaling in RC vs DC melanomas, confirming the  
37  
38 more aggressive behavior of RC vs DC subtype. Moreover, a substantial gene modulation  
39  
40 related to integrin and cadherin signaling pathways and angiogenesis was observed in CT vs.  
41  
42 RC melanomas. At the same time, a switch from E-cadherin to N-cadherin expression from DC  
43  
44 to CT melanomas was detected.

45  
46  
47  
48  
49 Altogether, our results strongly suggest the existence of a close correlation between RCM-  
50  
51 observed cell-morphology and tumor aggressiveness. Giving the slow-growing features of DC  
52  
53 melanoma (Argenziano et al., 2010), it could represent the less aggressive type of melanoma.  
54  
55 Conversely, a tumor that arises with a predominant RC population has a faster pattern of growth  
56  
57 and a shorter time to invasion (Pellacani et al., 2014). Subsequently, melanoma cells may  
58  
59  
60

1  
2  
3 undergo a de-differentiation step, creating less cohesive cells aggregated into the dermis,  
4  
5 corresponding to CT melanoma (Longo et al., 2013), confirmed by the higher expression of  
6  
7 stemness markers in this tumor-type vs. DC/RC melanomas.  
8  
9

10 The present study demonstrated that DN melanoma is a unique tumor subtype with peculiar  
11  
12 features. Although CT melanomas may share some morphological characteristics, i.e., small  
13  
14 cell dermal aggregates, called “cerebriform nests” (Pellacani et al, 2005), with DN-type,  
15  
16 biomolecular markers are significantly different. In fact, DN melanomas showed Ki67-positive  
17  
18 cells only in the dermis, without any epidermal change, and expressed highest levels of the  
19  
20 MICs markers, indicating a more undifferentiated state. Moreover, DN were significant more  
21  
22 invasive than CT *in vitro*, which was confirmed by the higher expression of  $\alpha4/\alpha7$ -integrin and  
23  
24 N-cadherin, as compared to CT. Interestingly, DN cells were able to attach and growth only  
25  
26 when seeded directly into the dermis in skin reconstructs. Accordingly, E-cadherin, an epithelial  
27  
28 adhesion molecule (Van Roy et al., 2014), was scarcely detected in DN melanoma. The peculiar  
29  
30 features of DN melanoma are coherent with the idea of the different origin of this tumor. It  
31  
32 could probably originate directly from dermal stem cells without an epidermal-RGP (Zalaudek  
33  
34 et al., 2008; Hoerter et al., 2012).  
35  
36  
37  
38  
39

40 To summarize, we believe that there are at least two main melanoma subtypes: (i) the  
41  
42 epidermal-origin type, which may arise as DC or RC type, with the potential to progress into  
43  
44 the CT-type developing invasive clones morphologically similar to DN-type melanoma, but  
45  
46 with different biomolecular profiles; and (ii) the dermal-origin type, characterized by DN  
47  
48 morphology upon RCM and the most aggressive biomolecular profile, as expressed by higher  
49  
50 level of MICs markers and higher expression of  $\alpha4/\alpha7$ -integrin and N-cadherin.  
51  
52  
53

54 This work reports the most comprehensive study on the correlation between RCM-observed  
55  
56 cell-morphology and bio-molecular behavior of melanoma, which accounts for diverse degree  
57  
58 of tumor aggressiveness. Moreover, these data confirm that *in vivo* RCM can be a dependable  
59  
60

1  
2  
3 tool for detecting different types of melanoma and for screening purposes. The findings of the  
4  
5 present study represent a first step to the creation of an integrated clinical/biomolecular model  
6  
7 of melanoma classification for reaching a more accurate patient/tumor tailored therapeutic  
8  
9 approach.  
10  
11  
12  
13

## 14 **Materials and Methods**

### 15 **Melanoma lesions retrieval**

16  
17  
18  
19 Melanoma cases for retrospective study were retrieved from the database of the Department of  
20  
21 Dermatology of the University of Modena and Reggio Emilia.  
22  
23

24  
25 Melanoma biopsies were provided by the Dermatology Surgery of the Policlinic of Modena  
26  
27 and Sassuolo Hospital. The use of melanoma biopsies was approved by the Ethical Committee  
28  
29 of Area Vasta Emilia Nord (Prot. N. 475, Doc. 118/14 – 09/02/2016).  
30

31  
32 Inclusion criteria, immunohistochemistry, culture methods and *in vitro* assay were fully  
33  
34 described in the supplementary materials.  
35  
36  
37

### 38 **NanoString and western blotting**

39  
40  
41 Total-RNA was extracted from histological sections. NanoString and computational  
42  
43 analysis was performed as described in supplementary materials. Total proteins were  
44  
45 extracted from cryopreserved melanoma biopsies and Western blot was performed as  
46  
47 indicated in supplementary materials.  
48  
49  
50

### 51 **Statistical analysis**

52  
53  
54 Statistical analysis was performed using STATA® software 14 or GraphPad Prism 9 as  
55  
56 indicated in supplementary materials. Data were considered significant with  $p < 0.05$  (\*),  
57  
58  $p < 0.01$  (\*\*) and  $p < 0.001$  (\*\*\*).  
59  
60

### **Data availability statement**

Data supporting the findings of this study are available from the corresponding author upon reasonable request. Datasets related to this study can be found at [<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE174395>] by using the following private token: qfohocyydbqvvt.

### **Conflict of interest**

Authors declare no conflict of interest.

### **Founding**

This work was supported by the AIRC grant IG 2015 (N. 16890).

### **Author contribution**

A.M, F.F, C.P and G.P designed the study. M.Q., A.M. performed most of the experiments and data analysis. F.F, S.C. and G.P performed RCM analysis and enrolled patients. F.F., M.P., C.M. and A.M.C provide melanoma samples. L.F. performed immunohistochemical reaction. M.Q, A.M and C.V. performed immunohistochemical analyses. E.P. and M.Q. performed computational analysis. S.K. performed statistical analysis. M.Q., A.M. and C.P. wrote the manuscript. All authors contributed to drafting and revising the article to give final approval.

### **References**

Argenziano G., Kittler H., Ferrara G., Rubegni P et al., Slow-growing melanoma: a dermoscopy follow-up study, *Br J Dermatol.*, 161 (2010); pp. 267-73. doi: 10.1111/j.1365-2133.2009.09416.x.

- 1  
2  
3 Arrangoiz R., Dorantes J., Cordera F., Juarez M. M., Pequentin E. M. De Leon E. L.  
4  
5 Melanoma Review: Epidemiology, Risk Factors, Diagnoses and Staging, Journal of  
6  
7 Cancer Treatment and Research, 4 (2016); pp. 1-15. DOI: 10.11648/j.jctr.20160401.11  
8  
9
- 10 Beretti F., Bertoni L., Farnetani F., Pellegrini C., Gorelli G., Cesinaro A.M., et al., Melanoma  
11  
12 types by in vivo reflectance confocal microscopy correlated with protein and molecular  
13  
14 genetic alterations: A pilot study, EXP Dermatol., 28 (2019); pp. 254-260. DOI:  
15  
16 10.1111/exd.13877.  
17  
18
- 19 Boiko A. D., O. V. Razorenova, M. Van De Rijn et al., Human melanoma-initiating cells  
20  
21 express neural crest nerve growth factor receptor CD271, Nature, 466 (2010); pp. 133–  
22  
23 137, 2010. DOI: 10.1038/nature09161  
24  
25
- 26 Bosserhoff A. K. , Ellmann L., Quast A. S., et al., Loss of T-cadherin (CDH-13) regulates  
27  
28 AKT signaling and desensitizes cells to apoptosis in melanoma, 53 (2013); pp. 635-47.  
29  
30 DOI: 10.1002/mc.22018  
31  
32
- 33 Broekaert S.M.C., Roy R., Okamoto I., et al., Genetic and morphologic features for  
34  
35 melanoma classification., Pigment Cell Melanoma Res., 23 (2010); pp. 763-770.  
36  
37 DOI: 10.1111/j.1755-148X.2010.00778.x  
38  
39
- 40 Caramel J, Papadogeorgakis E, Hill L, Browne GJ et al., A switch in the expression of  
41  
42 embryonic EMT-inducers drives the development of malignant melanoma *Cancer Cell*,  
43  
44 14 (2013); pp. 466-80. DOI: 10.1016/j.ccr.2013.08.018.  
45  
46
- 47 Chartrain M, Riond J, Stennevin A, Vandenberghe I, Gomes B, Lamant L, et al., Melanoma  
48  
49 chemotherapy leads to the selection of ABCB5-expressing cells., PLoS One, 7 (2012).  
50  
51 DOI: 10.1371/journal.pone.0036762  
52  
53
- 54 Clark W H, From L, Bernardino E A. The histogenesis and biologic behavior of primary  
55  
56 human malignant melanoma of the skin. Cancer Res, 29 (1969); pp. 705-27.  
57  
58  
59  
60

- 1  
2  
3 Eskens FA, Dumez H, Hoekstra R, et al., Phase I and pharmacokinetic study of continuous  
4  
5 twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor  
6  
7 of the integrins  $\alpha v \beta 3$  and  $\alpha v \beta 5$  in patients with advanced solid tumours.,  
8  
9 Eur J Cancer., 39 (2003); pp. 917-26. DOI: 10.1016/s0959-8049(03)00057-  
10  
11  
12 Fink C. and Haenssle., Non –invasive tools for the diagnosis of cutaneous melanoma., Skin  
13  
14 Reasearch and Technology, 3 (2016); pp. 261.271. DOI: 10.1111/srt.12350  
15  
16  
17 Gajos-Michniewicz A. and Malgorzata C., WNT signaling in melanoma., Int. J. Mol. Sci., 9  
18  
19 (2020); pp. 4852. DOI: 10.3390/ijms21144852.  
20  
21  
22 Graf S. A., Busch C., Bosserhoff A.K., et al., SOX10 Promotes Melanoma Cell Invasion by  
23  
24 Regulating Melanoma Inhibitory Activity, J. Invest. Dermatology., 134 (2014), pp. 2212-  
25  
26 2220. DOI: 10.1038/jid.2014.128.  
27  
28  
29 Grazziotin TC., Alarcon I., Bonamigo RR., Carrera C., Potrony M., Auguilera P., Puig-Butillé  
30  
31 J-A., Brito J., Badenas C., Alòs L., Malveyh J., Puig S., Association between confocal  
32  
33 morphologic classification and clinical phenotypes of multiple primary and familial  
34  
35 melanomas, JAMA Dermatology, 152 (2016); pp. 1099-1105. DOI:  
36  
37 10.1001/jamadermatol.2016.1189  
38  
39  
40 Haass NK, Smalley KS, Li L, Herlyn M., Adhesion, migration and communication in  
41  
42 melanocytes and melanoma., Pigment Cell Res., 18 (2005); pp. 150–159.  
43  
44 DOI: 10.1111/j.1600-0749.2005.00235.x.  
45  
46  
47 Hoerter J., Bradley P., Casillas A., et al., Extrafollicular dermal melanocyte stem cells and  
48  
49 melanoma., Stem Cells Int (2012). DOI: 10.1155/2012/407079.  
50  
51  
52 Javelaud D, Alexaki VI, Mauviel A., Transforming growth factor-beta in cutaneous  
53  
54 melanoma., Pigment Cell Melanoma Res., 21 (2008); pp. 123–132.  
55  
56  
57 Klein WM, Wu BP, Zhao S, et al., Increased expression of stem cell markers in malignant  
58  
59 melanoma., Mod Pathol, 20 (2007); pp. 102–107. DOI: 10.1038/modpathol.3800720.  
60

- 1  
2  
3 Longo C, Farnetani F, Ciardo S et al. Is confocal microscopy a valuable tool in diagnosing  
4  
5 nodular lesions? A study of 140 cases., *Br J Dermatol.*, 169 (2013); pp. 58-67.  
6  
7 DOI: 10.1111/bjd.12259  
8  
9  
10 Monzani E., F. Facchetti, E. Galmozzi et al., “Melanoma contains CD133 and ABCG2  
11  
12 positive cells with enhanced tumorigenic potential, *European Journal of Cancer*, 43  
13  
14 (2007); pp. 935–946. DOI: 10.1016/j.ejca.2007.01.017  
15  
16  
17 Pellacani G., De Pace B., Reggiani C., Cesinaro AM., Argenziano G., Zalaudek I., Soyer  
18  
19 H.P., Longo C. Distinct melanoma types based on reflectance confocal microscopy.  
20  
21 *Experimental Dermatology*, 2014. DOI: 10.1111/exd.12417.  
22  
23  
24 Pellacani G, Guitera P, Longo C, et al. The impact of in vivo reflectance confocal microscopy  
25  
26 for the diagnostic accuracy of melanoma and equivocal melanocytic lesions., *J Invest*  
27  
28 *Dermatol.* 127 (2007); pp. 2759-2765. DOI: 10.1038/sj.jid.5700993  
29  
30  
31 Pellacani G, Cesinaro AM, Seidenari S. In vivo assessment of melanocytic nests in nevi and  
32  
33 melanomas by reflectance confocal microscopy., *Mod Pathol.*, 18 (2005); pp. 469-74  
34  
35 DOI: 10.1038/modpathol.3800330  
36  
37  
38 Phyllis A. Gimotty, Patricia Van Belle, David E. Elder, et al., Biologic and Prognostic  
39  
40 Significance of Dermal Ki67 Expression, Mitoses, and Tumorigenicity in Thin Invasive  
41  
42 Cutaneous Melanoma., *Journal of Clinical Oncology*, 13 (2006); pp.8048-8056.  
43  
44 DOI: 10.1200/JCO.2005.02.0735  
45  
46  
47 Rajadhyaksha M, Grossman M, Esterowitz D, et al. In vivo confocal scanning laser  
48  
49 microscopy of human skin: melanin provides strong contrast., *J Invest Dermatol.*, 104  
50  
51 (1995); pp. 946-952. DOI: 10.1111/1523-1747.ep12606215  
52  
53  
54 Ramakrishnan V., Bhaskar V., Law D. A., et al., Preclinical evaluation of an anti- $\alpha 5\beta 1$   
55  
56 integrin antibody as a novel anti-angiogenic agent., *J Exp Ther Oncol.*, 5 (2006); pp. 273-  
57  
58 86.  
59  
60

1  
2  
3 Richmond A., Yang J., and Su Y., The good and the bad of chemokines/chemokine receptors  
4 in Melanoma., *Pigment Cell Melanoma Res.*, 22 (2009); pp. 175–186.

5  
6  
7 DOI:10.1111/j.1755-148X.2009.00554.x.

8  
9  
10 Rodriguez-Cerdeira C., Gregorio M. C., Lopez-Barcenas A. et al., Advances in  
11 Immunotherapy for Melanoma: A Comprehensive Review, *Mediat Inflamm.*, 207 (2017);  
12 pp.1-14. DOI: 10.1155/2017/3264217  
13  
14

15  
16  
17 Rusciano, D. Differentiation and metastasis in melanoma. *Crit. Rev. Oncog.*, 11 (2000); pp.  
18 147–163.

19  
20  
21 Saltari A., Truzzi F., Quadri M., Lotti R., Palazzo E. et al., CD271 Down-Regulation  
22 Promotes Melanoma Progression and Invasion in Three-Dimensional Models and in  
23 Zebrafish, *J. Invest. Dermatol.*, 136 (2016); pp.2049-2058.

24  
25  
26  
27  
28 DOI: 10.1016/j.jid.2016.05.116.

29  
30 Santini R, Pietrobono S, Pandolfi S, Montagnani V, D'Amico M, Penachioni JY et al., SOX2  
31 regulates self-renewal and tumorigenicity of human melanoma-initiating cells., *Oncogene*,  
32 33 (2014); pp. 4697–4708. DOI: 10.1038/onc.2014.71.  
33  
34  
35

36  
37 Schlegel J., Sambada M.J, Sather S. eta al., MERTK receptor tyrosine kinase is a therapeutic  
38 target in melanoma., *J Clin Investigation*, 123 (2013): pp. 2257-2267. DOI:  
39 10.1172/JCI67816.  
40  
41  
42

43  
44 Schlegel NC, von Planta A, Widmer DS, Dummer R, Christofori G. PI3K signalling is  
45 required for a TGF $\beta$ -induced epithelial-mesenchymal-like transition (EMT-like) in human  
46 melanoma cells., *Exp Dermatol.*, 24 (2015); pp.22–28. DOI: 10.1111/exd.12580  
47  
48  
49

50  
51 Scolyer R.A., Long G. V., Thompson J.F.; Evolving concepts in melanoma classification and  
52 their relevance to multidisciplinary melanoma patient care., *Molecular Oncology* (2011);  
53 pp. 124-136. DOI: 10.1016/j.molonc.2011.03.002.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Takeuchi H., Morton D. L., Elashoff D., Hoon D. S. B., Survivin expression by metastatic  
4 melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent  
5 vaccine. *Int. J. Cancer*, 117 (2005), pp.1032–1038. DOI: 10.1002/ijc.21267  
6  
7  
8  
9  
10 Thompson J.F., Scolyer R.A., and Kefford R.F. Cutaneous melanoma., *Lancet*, 365 (2005);  
11 pp. 687-701. DOI: 10.1016/S0140-6736(05)17951-3  
12  
13  
14 Ugurel S, Rappel G, Tilgen W, Reinhold U., Increased serum concentration of angiogenic  
15 factors in malignant melanoma patients correlates with tumor progression and survival., *J.*  
16 *Clin. Oncol.*, 19 (2001); pp. 577–583. DOI: 10.1200/JCO.2001.19.2.577  
17  
18  
19  
20  
21 Van Roy F., Beyond E-cadherin: roles of other cadherin superfamily members in cancer., *Nat*  
22 *Rev Cancer*, 14 (2014); pp. 121–34. DOI: 10.1038/nrc3647.  
23  
24  
25  
26 Whiteman D.C., Pavan W.J., Boris C. and Bastian C., The melanomas: a synthesis of  
27 epidemiological, clinical, histopathological, genetic, and biological aspects, supporting  
28 distinct subtypes, casual pathways, and cells of origin, *Pigment Cell Melanoma Res.* 24  
29 (2011); pp. 879-897. DOI: 10.1111/j.1755-148X.2011.00880.x.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Widmer D.S., Hoek K., Cheng D.S., Eichhoff O. M., Biedermann T., et al., Hypoxia  
contributes to melanoma heterogeneity by triggering HIF1 $\alpha$ -dependent phenotype  
switching., *J. Invest Dermatol.*, 133 (2013); pp. 2436-2443 DOI: 10.1038/jid.2013.115
- Zalaudek I., Marghoob A. A., Scope A., et al., Three roots of melanoma., *Arch Dermatol.*,  
144 (2008); pp. 1375-9. DOI: 10.1001/archderm.144.10.1375.

## Table

Table 1. Association between RCM melanoma subtypes and clinical characteristics.

		DC (n=25)		RC (n=25)		DN (n=15)		CT (n=25)		Total		p-value
<b>Age, mean <math>\pm</math>SD (Range)</b>		69.2 $\pm$ 12.2 (47-88)		52.6 $\pm$ 15.9 (30-89)		55.6 $\pm$ 15.3 (31-78)		64 $\pm$ 18.2 (24-90)		60.9 $\pm$ 16.8 (24-90)		0.001
<b>Sex</b>		N	%	N	%	N	%	N	%	N	%	p-value
	<b>Female</b>	8	32.0	12	48.0	7	46.7	8	32.0	35	38.9	0.521
	<b>Male</b>	17	68.0	13	52.0	8	53.3	17	68.0	55	61.1	
<b>Tumor type</b>												
	<b>RGP</b>	23	92.0	14	56.0	1	6.7	1	4.0	39	43.3	<0.001
	<b>VGP</b>	2	8.0	11	44.0	14	93.3	24	96.0	51	56.7	
<b>Tumor site</b>												
	<b>Arts</b>	4	16.0	10	40.0	8	53.3	10	40.0	32	35.6	0.022
	<b>Face</b>	7	28.0	0	0.0	1	6.7	2	8.0	10	11.1	
	<b>Trunk</b>	14	56.0	15	60.0	6	40.0	13	52.0	48	53.3	
<b>BRAF<sup>V600E</sup></b>		6	24.0	18	72.0	7	46.6	14	56.0	45	51.1	0.007
<b>BRESLOW, n, mean <math>\pm</math>SD(Range)</b>		25, 0.2 $\pm$ 0.3 (0-1.04)		25, 0.6 $\pm$ 0.4 (0-2)		15, 5.8 $\pm$ 7.1 (0.65-24)		25, 2.6 $\pm$ 2.0 (0.5-8)		88, 2.0 $\pm$ 3.6 (0-24)		<0.001
<b>Breslow Index</b>		N	%	N	%	N	%	N	%	N	%	
	<b>mm<math>\leq</math>1</b>	24	96.0	22	88.0	1	6.7	5	20.0	50	55.6	<0.001
	<b>1&lt;mm<math>\leq</math>2</b>	1	4.0	3	12.0	3	20.0	8	32.0	15	16.7	
	<b>2&lt;mm<math>\leq</math>4</b>	0	0.0	0	0.0	6	40.0	7	28.0	13	14.4	
	<b>5&lt;mm<math>\leq</math>10</b>	0	0.0	0	0.0	2	13.3	0	0.0	2	2.2	
	<b>mm&gt;10</b>	0	0.0	0	0.0	3	20.0	5	20.0	8	8.9	
<b>Clark Level</b>												
	<b>I</b>	11	44.0	1	4.0	0	0.0	0	0.0	12	13.3	<0.001
	<b>II</b>	11	44.0	12	48.0	1	6.7	1	4.0	25	27.8	
	<b>III</b>	3	12.0	10	40.0	5	33.3	8	32.0	26	28.9	
	<b>IV</b>	0	0.0	2	8.0	7	46.7	13	52.0	22	24.4	
	<b>V</b>	0	0.0	0	0.0	2	13.3	3	12.0	5	5.6	
<b>Mitotic Index</b>												
	<b>0-1</b>	24	96.0	24	96.0	5	33.3	9	36.0	60	66.7	<0.001
	<b>2-5</b>	1	4.0	1	4.0	7	46.7	10	40.0	19	21.1	
	<b>&gt;5</b>	0	0.0	0	0.0	3	20.0	6	24.0	9	10.0	
<b>Previous history of M</b>		9	36.0	2	8.0	1	6.7	0	0.0	12	13.3	0.001
<b>Posive sentinel lymph node</b>		0	0.0	2	8.0	4	26.7	8	32.0	14	15.6	0.013
<b>Follow up</b>												
<b>Relaps or new M</b>		10	40.0	2	8.0	4	26.7	3	12.0	17	18.9	0.118
<b>Metastasis 0-5 years</b>		0	0.0	1	4.0	5	33.3	5	20.0	11	12.2	0.005

1  
2  
3 Abbreviation: DC, Dendritic cell melanoma; RC, Round cell melanoma; CT, Combined type  
4 melanoma; DN, Dermal Nest Melanoma; M, Melanoma; SD, Standard Deviation; N, Number;  
5  
6  
7 RGP, Radial Growth Phase; VGP, Vertical Growth Phase.  
8  
9

## 10 11 12 **Figure Legends**

### 13 14 15 **Figure 1. Representative clinical, histopathological and RCM images of melanoma**

16  
17 **subtype.** DC: **a, b)** Clinical and Dermoscopic image of Lentigo Maligna (LM). **c)** RCM  
18 image of melanoma in the transition from epidermis to DEJ shows numerous lines  
19 corresponding to dendritic cells (red rectangle and red arrows), coming out of the hair  
20 follicles (asterisk). **(d-f)** Hematoxylin and eosin (H&E), HMB45 and Melan-A staining.  
21  
22 Scale bar 50µm. RC: **a-b)** Clinical and Dermoscopic image of Melanoma. **c)** RCM shows  
23 the presence of several roundish large melanocytes (red rectangle and red arrows) with  
24 bright cytoplasm and hypo-reflective nucleus. **d-f)** H&E and HMB45, Melan-A staining.  
25  
26 Scale bar 50µm. CT: **a-b)** Clinical and Dermoscopic image of Melanoma. **c)** RCM shows  
27 the presence of dendritic cells, roundish cells (red rectangle and red arrows) and  
28 polymorphic cells (green arrow) within the dermal papilla. **d-f)** H&E and HMB45,  
29  
30 Melan-A staining. Scale bar 50µm. DN: **a-b)** Clinical and Dermoscopic image of  
31  
32 Melanoma. **c)** RCM shows the presence of a cerebriform nesting (red rectangle and red  
33  
34 arrows) located at the dermal level. **d-f)** H&E, HMB45 and Melan-A staining. Scale bar  
35  
36 500µm.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 53 **Figure 2. Correlation between RCM melanoma subtypes to markers expression and**

54  
55 **biological behaviour in vitro.** **(a)** The expression of Ki67, MERTK, Nestin, Hif-1 $\alpha$ , ABCB5  
56  
57 and **(b)** SOX-10, SOX-2, CD133 and CD271 were evaluated by IHC. Protein expression was  
58  
59 scored 0 to 4 and the average positive cells was calculated for each individual melanoma as  
60

1  
2  
3 follow: 0 score, 0% staining melanoma cells; 1=1%-25% staining positive melanoma cells;  
4  
5 2=26%-50% staining positive melanoma cells; 3=51-75% staining-positive melanoma cells and  
6  
7 4=76%-100% staining positive melanoma cells. Scale bar 50 $\mu$ m. (c) Melanoma biopsies were  
8  
9 digested and approximately 10<sup>4</sup> cells were seeded for spheroid formation. (d) Total spheroids  
10  
11 area was measured by ImageJ software and (e) MTT assay was performed at different time  
12  
13 points.  
14  
15  
16  
17  
18

19 **Figure 3. Gene expression profile of RCM melanoma subtypes.** (a) Heatmaps representing  
20  
21 the main GO BP terms identified by DAVID Functional Association Tool. Gene expression  
22  
23 values for each heatmap were ranked according to their z-score after normalization. The gene  
24  
25 expression was showed as raw value of normalized intensity. (b) Differently expressed genes  
26  
27 were uploaded onto Venny 2.1 tool. RC, CT and DN melanomas were compared to DC  
28  
29 melanoma (Venny diagram on the left). The gene list resulting modulated in each group  
30  
31 obtained from Venny were uploaded on PANTHER Classification System. The five more  
32  
33 significant modulated pathways were reported in (b) upregulated and (c) downregulated  
34  
35 pathways: 1) RC vs DC, 2) CT vs DC, 3) DN vs DC and 4) common up or down regulated  
36  
37 pathways. (d) The expression levels of *BIRC5* (Survivin), *CXCL8* and *NGFR* (CD271) mRNA  
38  
39 were evaluated by Real-Time PCR in each RCM-melanoma subtype.  
40  
41  
42  
43  
44  
45  
46

47 **Figure 4. Correlation between RCM-observed morphology and tumor aggressiveness.** (a)  
48  
49 Up and down regulated genes in RC vs DC comparison were uploaded on PANTHER  
50  
51 Classification System. The five more significant modulated pathways were reported in: 1)  
52  
53 upregulated and 2) downregulated pathways. Graphs on the right represent the fold change of  
54  
55 each gene clustered on the base of the pathway involved. (b) CT vs RC differently expressed  
56  
57 genes were uploaded on PANTHER Classification System. Genes were clustered based on the  
58  
59  
60

1  
2  
3 main significant pathway involved: 1) upregulated and 2) downregulated pathways. Graphs  
4  
5 on the right represent the fold change of each gene clustered on the base of the pathway  
6  
7 involved. (c) DC, RC, and CT melanoma samples were retrieved. HMB45 and CD271  
8  
9 expression were evaluated by IHC. Scale bar 50 $\mu$ m. (d) Correlation between Breslow index  
10  
11 and CD271 expression level. (e) Proteins were extracted from DC, RC, and CT melanoma  
12  
13 biopsies and immunoblotting for E and N-cadherin was performed, using  $\beta$ -actin as normalizing  
14  
15 protein.  
16  
17  
18  
19  
20

21  
22 **Figure 5. Differences between the most aggressive RCM-melanoma subtypes.** (a) Up and  
23  
24 downregulated genes in CT vs DN comparison was uploaded on PANTHER Classification  
25  
26 System. Genes were clustered based on the main significant pathway involved: 1) upregulated  
27  
28 and 2) downregulated pathways. Graphs on the right represent the fold change of each gene  
29  
30 clustered on the base of the pathway involved. (b) CT and DN spheroids were transferred in a  
31  
32 type I collagen matrix and pictures were taken at different time. (c) Total spheroids area (d) the  
33  
34 percentage of fragmentation and (e) cells invading area were evaluated by ImageJ softwar. (f)  
35  
36 the invasion distance reached by cells from spheroids were measured by GIMP software. (g)  
37  
38 CT and DN cells were employed to reconstruct melanoma skin equivalent. After 14 days of  
39  
40 emersion conditions, melanoma skin equivalents were paraffin embedded and sections were  
41  
42 stained with H&E, Melan-A and HMB45 by IHC. Scale Bar 50  $\mu$ m. (h) The expression of  
43  
44 MIB/Ki67, E and N-cadherin,  $\alpha_7$ -integrin,  $\alpha_4$ -integrin, and SOX-2 were revealed by IF and  
45  
46 measured by ImageJ software. (i) DN spheroids were transferred in a type I collagen matrix  
47  
48 and, after 336h, fixed with PFA 4%. The expression of  $\alpha_4$ -integrin (red) and CD271 (green)  
49  
50 were revealed by IF. Scale Bar 100  $\mu$ m.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Representative clinical, histopathological and RCM images of melanoma subtype. DC: a, b) Clinical and Dermoscopic image of Lentigo Maligna (LM). c) RCM image of melanoma in the transition from epidermis to DEJ shows numerous lines corresponding to dendritic cells (red rectangle and red arrows), coming out of the hair follicles (asterisk). (d-f) Hematoxylin and eosin (H&E), HMB45 and Melan-A staining. Scale bar 50um. RC: a-b) Clinical and Dermoscopic image of Melanoma. c) RCM shows the presence of several roundish large melanocytes (red rectangle and red arrows) with bright cytoplasm and hyporeflective nucleus. (d-f) H&E and HMB45, Melan-A staining. Scale bar 50um. CT: a-b) Clinical and Dermoscopic image of Melanoma. c) RCM shows the presence of dendritic cells, roundish cells (red rectangle and red arrows) and polymorphic cells (green arrow) within the dermal papilla. d-f) H&E and HMB45, Melan-A staining. Scale bar 50um. DN: a-b) Clinical and Dermoscopic image of Melanoma. c) RCM shows the presence of a cerebriform nesting (red rectangle and red arrows) located at the dermal level. d-f) H&E, HMB45 and Melan-A staining. Scale bar 50um.

180x220mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Correlation between RCM melanoma subtypes to markers expression and biological behaviour in vitro. (a) The expression of Ki67, MERTK, Nestin, Hif-1 $\alpha$ , ABCB5 and (b) SOX-10, SOX-2, CD133 and CD271 were evaluated by IHC. Protein expression was scored 0 to 4 and the average positive cells was calculated for each individual melanoma as follow: 0=0% staining melanoma cells; 1=1%-25% staining positive melanoma cells; 2=26%-50% staining positive melanoma cells; 3=51-75% staining positive melanoma cells and 4=76%-100% staining positive melanoma cells. Scale bar 50 $\mu$ m. (c) Melanoma biopsies were digested and approximately 104 cells were seeded for spheroid formation. (d) Total spheroids area was measured by ImageJ software and (e) MTT assay was performed at different time points.

180x220mm (300 x 300 DPI)




Figure 3. Gene expression profile of RCM melanoma subtypes. (a) Heatmaps representing the main GO BP terms identified by DAVID Functional Association Tool. Gene expression values for each heatmap were ranked according to their z-score after normalization. The gene expression was shown as raw value of normalized intensity. (b) Differently expressed genes were uploaded onto Venny 2.1 tool. RC, CT and DN melanomas were compared to DC melanoma (Venny diagram on the left). The gene list resulting modulated in each group obtained from Venny were uploaded on PANTHER Classification System. The five more significant modulated pathways were reported in (b) upregulated and (c) downregulated pathways: 1) RC vs DC, 2) CT vs DC, 3) DN vs DC and 4) common up or down regulated pathways. (d) The expression levels of BIRC5 (Survivin), CXCL8 and NGFR (CD271) mRNA were evaluated by Real-Time PCR in each RCM-melanoma subtype.

179x220mm (300 x 300 DPI)




Figure 4. Correlation between RCM-observed morphology and tumor aggressiveness. (a) Up and down regulated genes in RC vs DC comparison were uploaded on PANTHER Classification System. The five more significant modulated pathways were reported in: 1) upregulated and 2) downregulated pathways. Graphs on the right represent the fold change of each gene clustered on the base of the pathway involved. (b) CT vs RC differently expressed genes were uploaded on PANTHER Classification System. Genes were clustered based on the main significant pathway involved: 1) upregulated and 2) downregulated pathways. Graphs on the right represent the fold change of each gene clustered on the base of the pathway involved. (c) DC, RC, and CT melanoma samples were retrieved. HMB45 and CD271 expression were evaluated by IHC. Scale bar 50um. (d) Correlation between Breslow index and CD271 expression level. (e) Proteins were extracted from DC, RC, and CT melanoma biopsies and immunoblotting for E and N-cadherin was performed, using β-actin as normalizing protein.

180x220mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

180x220mm (300 x 300 DPI)

## SUPPLEMENTARY MATERIALS

### Materials and Methods

#### Melanoma lesion retrieval

Melanoma cases were retrieved from the database of the Department of Dermatology of the University of Modena and Reggio Emilia. Inclusion criteria were: 1) confirmed diagnoses of melanoma, 2) availability of relevant clinical data in patient records and 3) histological, dermoscopic and confocal images.

Clinical, dermoscopic and RCM images were acquired through a Canfield Nikon D90 Digital SLR®, a Canfield Close-up Scale® (Canfield Imaging Systems, Fairfield, NJ, USA) and an RCM laser scanning microscope (Vivascope 1500®; MAVIG GmbH, Munich, Germany), respectively, and were stored in a dedicated database. RCM employs an 830nm laser beam with a maximum power of 20mW. Instrument and acquisition procedures were previously described (Rajadhyaksha et al., 1999; Pellacani et al., 2007). A minimum of 3 mosaics were obtained per lesion at 3 different depths, corresponding to the superficial epidermal layer (the stratum granulosum/spinosum), dermal-epidermal junction (DEJ), and papillary dermis. Each image was blindly evaluated by expert dermatologist for epidermal, DEJ and upper dermis architecture and classified into four melanoma subtypes, as previously reported (Pellacani et al., 2014).

#### Immunohistochemistry (IHC)

Melanoma markers were detected using UltraView Universal DAB and RED detection Kit (Ventana Medical Systems, Roche diagnostics International AG, Rotkreuz, Switzerland); except for BRAF mutation and CD271. The Opti-View DAB IHC detection kit were used to detect BRAF mutation (Ventana Medical Systems), while Fast Red kit UltraVision LP Detection System AP Polymer & Fast Red Chromogen (Thermo Fisher Scientific, Waltham, MA, USA) was used to detect CD271,

1  
2  
3 according to the manufacturer's protocol. Primary antibodies were listed in Supplementary Table S1.  
4  
5 Images of the H&E and IHC-staining were obtained by a D-Sight slide scanner (Menarini  
6  
7 Diagnostics, Firenze, Italy).  
8  
9

### 12 **Melanoma biopsies digestion and culture methods**

14 Melanoma biopsies were provided by the Dermatology Surgery of the Policlinic of Modena  
15 and Sassuolo Hospital. The use of melanoma biopsies was approved by the Ethical Committee  
16 of Area Vasta Emilia Nord (Prot. N. 475, Doc. 118/2014 – 09/02/2016). Biopsies was digested  
17 in a mix of collagenase I and IV (1:2000 and 1:500, respectively) (Gibco, Thermo Fisher  
18 Scientific) and cells were seeded and cultured using hanging drop or liquid overlay methods in  
19 RMPI medium supplemented with 10% of heat-inactivated serum, 2% of L-Glutamine and 1%  
20 of Penicillin/Streptomycin (Lonza, Basel, Switzerland).  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 MTT assay was performed to evaluate RCM-melanoma spheroids from 24 hours to 168 hours.  
31  
32 Collagen invasion assay was used to assess the invasion ability of melanoma cells within a collagen  
33 I matrix. The area occupied by melanoma spheroids and the invasive capacity of cells were evaluated  
34 by ImageJ program (NIH), as previously indicated (Saltari et al., 2016).  
35  
36  
37  
38  
39  
40  
41

### 42 **NanoString and computational analyses**

44 Total RNA was extracted from Formalin-Fixed Paraffin-Embedded samples by using RNeasy  
45 FFPE kit (Quiagen, Hilden, Germany), following the manufacturer's instruction. 32 samples  
46 were employed (9 for DC, 6 for RC, 7 for DN and 10 for CT). 10 slices of 10uM per patients  
47 were employed and only tumoral area was collected. cDNA was prepared using the High-  
48 Capacity cDNA Reverse Transcription kit (Applied Biosystem, Foster City, CA, USA) and  
49 Real-Time PCR was performed using the DyNamo SYBR Green qPCR kit (Thermo Fisher  
50 Scientific, Waltham, MA, USA). Genes primers sequences are listed in Table S2.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 NanoString nCounter technology was performed by PharmaDiagen team (Pordenone, Italy) and  
4 the analysis was focused on 770 genes (nCounter PanCancer Progression Panel). Biological  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

NanoString nCounter technology was performed by PharmaDiagen team (Pordenone, Italy) and the analysis was focused on 770 genes (nCounter PanCancer Progression Panel). Biological Process enrichment of significant modulated genes was identified through DAVID Functional Annotation Tools (<https://david.ncifcrf.gov>). All Heatmaps were generated with Excel. Venny diagram was created by Venny 2.1 Tool (<http://bioinfogp.cnb.csic.es/tools/venny>) and pathway enrichment were generated with Panthers Classification System (<http://pantherdb.org/>).

### Western blot analysis

Total proteins were extracted from cryopreserved melanoma biopsies and lysed in buffer pH 7.5. 10  $\mu$ g of protein were separated on SDS-PAGE gels, transferred to nitrocellulose membranes (Bio-Rad Laboratories, Inc, Hercules, CA, USA), and incubated with primary antibodies (listed in Table S1) and then with peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies (Bio-Rad Laboratories). Proteins were visualized using Chemidoc MP Imager (Bio-Rad Laboratories) after incubation with ECL detection system (Pierce Biotechnology, Fisher Scientific International Inc., Hampton, NH, USA)

### Melanoma skin reconstructs.

For dermal reconstructs, 0.5 ml of a cell free collagen solution (1.35 mg/ml rat tail type I collagen in DMEM with 10% FBS and 1% Pen/Strep) was added to tissue culture inserts (Transwell, Costar, Cambridge, MA) in 12-well plates. This pre-coated layer was overlaid with 1ml of fibroblasts mixed with collagen type I solution ( $15 \times 10^4$ /ml). In case of DN melanoma, spheroids were implanted in the dermal equivalent and after 4 days of incubation at 37°C, primary human keratinocytes ( $25 \times 10^4$  cells) were seeded on it to form epidermal equivalent. As concern for CT melanoma, human keratinocytes and CT melanoma cells ( $5 \times 10^4$  cells) were seeded together on dermal reconstructs. Finally, skin reconstructs were exposed to the air and medium was changed every two days. After either 6 or 12

1  
2  
3 days, skin reconstructs were fixed with formalin for 2 h at room temperature, dehydrated and  
4  
5 embedded in paraffin.  
6  
7  
8  
9

### 10 **Statistical analysis**

11  
12 For clinical data, statistical analysis was performed using STATA® software version 14  
13 (StataCorp. 2015. Stata Statistical Software: Release 14. StataCorp LP, College Station, TX,  
14 USA). Descriptive statistics were presented for baseline demographic clinical characteristics  
15 for the entire group. Means and standard deviations were calculated for normally distributed  
16 data while medians and 1st and 3rd quartiles were calculated for data that were not normally  
17 distributed. Continuous variables were presented as the number of patients (N), mean, standard  
18 deviation (SD), minimum (min), and maximum (max) and compared between subgroups using  
19 Unpaired Student's t test for two group; while categorical variables were presented as frequency  
20 (N, percentage [%]) and compared using Pearson's chi-squared test. A  $p < 0.05$  was considered  
21 statistically significant.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 For other data, the results are presented as mean  $\pm$  SD from three independent experiments.  
36  
37 Statistical analysis was performed with One-way ANOVA and Student's T-test by using  
38 GraphPad Prism 9 (GraphPad software, La Jolla California, USA). Significant p-values are  
39 indicated with \* for  $p < 0.05$ , \*\* for  $p < 0.01$  and \*\*\* for  $p < 0.001$ .  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


**Table S1:** List of Primary antibody used in the study.

Antibody	Provider	Dilution	Application
HMB45	Ventana, Roche (Rotkreuz, Switzerland)	Ready to use	IHC
Melan-A	Ventana, Roche	Ready to use	IHC
BRAF <sup>V600E</sup>	Ventana, Roche	Ready to use	IHC
Ki67	Dako, Agilent (Santa Clara, CA, USA)	1:200	IHC
MERTK	MilliporeSigma, (Burlington, MS, USA)	1:100	IHC
NESTIN	Arigo Biolaboratories (Hsinchu City, Taiwan)	1:100	IHC
HIF-1 $\alpha$	Novus Biologicals (Centennial, CO, USA)	1:50	IHC
ABCB5	Novus Biologicals	1:100	IHC
SOX-10	Novus Biologicals	1:200	IHC
SOX-2	Novus Biological	1:200	IHC/IF
CD133	Biorbyt (St Louis, MO, USA)	1:100	IHC
CD271	MilliporeSigma	1:100	IHC
E-CADHERIN	BD Bioscience (San Jose, CA, USA)	1:100 1:1000	IHC / IF WB
N-CADHERIN	BD Bioscience	1:100 1:1000	IHC / IF WB
$\alpha$ 7 INTEGRIN	Santa Cruz Biotechnology (Dallas, TX, USA)	1:100 1:1000	IHC / IF WB
$\alpha$ 4 INTEGRIN	Santa Cruz Biotechnology	1:100 1:1000	IHC / IF WB

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60**Table S2: Primers for Real-Time PCR**


	<b>Forward primer</b>	<b>Reverse primer</b>
<i>βactin</i>	TGG ATG ATG ATA TCG CCG CGC TCG	CAC ATA GGA ATC CTT CTG ACC CA
<i>NGFR</i>	TGA GTG CTG CAA AGC CTG CAA	TCT CAT CCT GGT AGT AGC CGT
<i>BIRC5</i>	GCA TGG GTG CCC CGA CGT TG	GCT CCG GCC AGA GGC CTC AA
<i>CXCL8</i>	GAATGGGTTTGCTAGAAATGTGATA	CAGACTAGGGTTGCCAGATTTAAC

For Review Only




**Figure S1. Panther pie chart of up-regulated gene in RCvsDC, CTvsDC and DNvsDC comparison.** Differentially expressed genes within RCvsDC, CTvsDC and DNvsDC comparisons were analyzed by Venny 2.1 tool. Gene list from each comparison was subsequently uploaded on PANTHER Classification System to generate a "Pathway" pie chart. The percentage of gene hit against total Pathway hits was reported for the top five up-regulated pathways (underlined).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure S2. Panther pie chart of down-regulated gene in RCvsDC, CTvsDC and DNvsDC comparison.** Differently expressed genes in RCvsDC, CTvsDC and DNvsDC comparison were uploaded onto Venny 2.1 tool. The gene list resulting modulated in each group obtained from Venny were uploaded on PANTHER Classification System to generate a pie chart related to involved pathways. Percent of gene hit against total Pathway hits were reported for the top five more up-regulated pathways (underlined).




**Figure S3. Panther pie chart of up and down-regulated gene in RC-DC and, CT-RC comparison.** Differently expressed genes in (a) RCvsDC and (b) CTvsRC melanomas were uploaded on PANTHER Classification System to generate a pie chart related to involved pathways. Percent of gene hit against total Pathway hits were reported for the five more up-regulated pathways (underlined)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure S4. Panther pie chart of up and down-regulated gene in CT versus DN melanoma.**

Up-regulated and down-regulated genes in CT versus DN were uploaded on PANTHER Classification System to generate a pie chart related to involved pathways. Percent of gene hit against total Pathway hits were reported for the five more up-regulated pathways (underlined).



18 **Figure S5. Collagen invasion assay of the most aggressive RCM-Subtypes.** CT and DN  
19 melanoma biopsies were digested, and cells were seeded in hanging drop culture to obtain  
20 spheroids. 72 h after seeding, spheroids were transferred in a type I collagen matrix and pictures  
21 were taken from 0 to 332 hours.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure S6. Schematic representation of the RCM-melanoma subtypes bio-molecular features and gene modulation.**

View Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60